ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05886244
- Locations
- 🇨🇳
Research Site, Wuhan, China
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05876351
- Locations
- 🇨🇳
Research Site, Wuhan, China
A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05780645
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05751642
- Locations
- 🇳🇿
Research Site, Christchurch, New Zealand
🇳🇿Clinical Trial Site, Grafton, Auckland, New Zealand
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 736
- Registration Number
- NCT05746559
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Potential Drug Interaction Between ALXN2040 and Rosuvastatin
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05708573
- Locations
- 🇺🇸
Clinical Trial Site, Baltimore, Maryland, United States
Early Access Program for ALXN1840 in Patients With Wilson Disease
- Conditions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT05686564
US Selumetinib Registry
Recruiting
- Conditions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05683678
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05644561
- Locations
- 🇨🇭
Research Site, Bern, Switzerland
Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05641311
- Locations
- 🇬🇧
Richmond Pharmacology Ltd., St George's University of London, London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath